TransMedics to Present at Canaccord Genuity Growth Conference
TransMedics Group, Inc. will participate in Canaccord Genuity's 46th Annual Growth Conference. The company focuses on organ transplant therapy technology.
Andover, Massachusetts – TransMedics Group, Inc. (Nasdaq: TMDX) announced its participation in Canaccord Genuity's 46th Annual Growth Conference. The conference is scheduled to take place virtually from September 10-12, 2024.
TransMedics, a medical technology company specializing in organ transplant therapy, aims to transform treatment options for patients with end-stage lung, heart, and liver failure. The company's core technology is the "Organ Care System" (OCS), designed to preserve donor organs outside the body, keeping them viable and functioning during transport.
During the conference, TransMedics representatives are expected to provide an overview of the company's strategic priorities and future outlook. The presentation will likely discuss recent clinical advancements and commercial performance, offering insights into the company's progress in the organ transplant field.
The Canaccord Genuity Annual Growth Conference brings together a range of growth-oriented companies and institutional investors. TransMedics' presence at this event highlights its commitment to engaging with the investment community and communicating developments in its transplant technology platform.